Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 6.14%
As of Friday, October 16, Revolution Medicines, Inc.’s RVMD share price has dipped by 6.14%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Revolution Medicines, Inc. (RVMD)
Revolution Medicines, Inc. RVMD
$177.01
-12.25
-6.47%
October 16, 2026 2:01:27 PM
EST
Volume: 1,352,356
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 8.65%
As of Thursday, October 08, Revolution Medicines, Inc.’s RVMD share price has dipped by 8.65%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.16%
As of Tuesday, October 06, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.98%
As of Friday, August 28, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.01%
As of Thursday, July 23, Revolution Medicines, Inc.’s RVMD share price has surged by 5.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $40,565.3 | $216.5 | 92% |
|
| Shares Out (Mil) | 210.9 | 53.9 | 77% |
|
| Institutional Ownership | 97.6% | 93.0% | 74% |
|
| Float (Mil) | 184.6 | 40.9 | 72% |
|
| Beta | 1.41 | 0.95 | 80% |
|
| Avg Daily Volume (000s) | 2,152 | 616 | 82% |
|
| Price Change (52-week) |
298.4% | 46.9% | 99% |
|
| Growth | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (59.9%) | (10.2%) | 5% |
|
| EPS (5yr) | (24.2%) | 15.7% | 11 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (20.3%) | (15.7%) | 33% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 20 | 23 | 23 | |
| Current EPS | ($2.396) | ($9.601) | ($5.648) | |
| Month Ago EPS | ($2.413) | ($9.741) | ($6.081) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.973) | ($8.034) | ($5.733) | |
| Year/Year Chg | (21.6%) | 61.4% | (63.3%) | |
| Financials | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($1,768) | ($44) | 1% |
|
| EPS (TTM) | ($8.921) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($1,223) | ($33) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $414 | $2 | 89% |
|
| Long-Term Debt (Q1) (Mil) | $1,174 | $4 | 68% |
|
| Enterprise Value (Q1) (Mil) | $38,180 | $174 | 90% |
|
| Valuation | RVMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 15.56 | 2.21 | 94% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (52.4%) | (47.2%) | 11% |
|
| ROE | (79.1%) | (54.2%) | 11% |
|
| Liabilities to Assets | 39.7% | 29.1% | 30% |
|
| F-Score | 1 | 2 | 1% |
|
Revolution Medicines, Inc. did not pass any screens on 10/15/2026.
